Trimerbody formating services

The plug-and-play nature of LeadArtis technology enables the rapid creation of more powerful, more effective antibodies by simply incorporating the binding domains of pre-existing antibodies to the selected Trimerbody scaffold of our structure-based design. So far, all selected antigen binding domains incorporated into the Trimerbody scaffold have dramatically enhanced biological function compared to the parental antibody. A growing pipeline could be based on this approach to creating differentiated antibody drug candidates.
 
LeadArtis’s broad portfolio of Trimerbody formats are compatible with nearly any conventional antibody, single domain antibody or antibody mimetic. Trimerbody formatting provides enhanced performance in therapeutic antibody programs in preclinical and clinical development for the treatment of cancer, inflammatory and autoimmune disorders.
 
LeadArtis extends the use of the Trimerbody technology through licenses to interested partners. For instance, some partners advancing programs in clinical trials and numerous pre-clinical projects might consider Trimerbody as a backup program to reduce toxicity, extend circulatory half-life, improve stability and solubility, or add new binding domains (e.g. addition of tumor targeting) 

Latest News

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021

Anglonordic is a great event to meet quality investors and companies - it is very well run and...